Analystreport

Allogene Therapeutics Inc (NASDAQ: ALLO) was upgraded by analysts at Roth Capital from a "neutral" rating to a "buy" rating.

Allogene Therapeutics, Inc.  (ALLO) 
Last allogene therapeutics, inc. earnings: 2/27 04:30 am Check Earnings Report